A single-cell transcriptional gradient in human cutaneous memory T cells restricts Th17/Tc17 identity

Graphical abstract

Highlights
- Psoriatic Th17/Tc17 cells dampen an inflammation-suppressive program (ZIST)
- Knockout of ZIST transcripts ZFP36L2, ZFP36 in T cells induces Th17/Tc17 cytokines
- IL23 blockade fails to normalize attenuated ZIST levels in healed psoriasis lesions

Authors
Christopher P. Cook, Mark Taylor, Yale Liu, ..., Silvia B.V. Ramos, Jeffrey B. Cheng, Raymond J. Cho

Correspondence
Jeffrey.Cheng@ucsf.edu (J.B.C.), raymond.cho@ucsf.edu (R.J.C.)

In brief
Cook et al. show that Th17/Tc17 expression occurs in a gradient within psoriatic single T cells, paralleled by attenuation of an inflammation-suppressive gene-expression program termed ZIST. Persistent ZIST suppression, even in therapeutically improved psoriatic lesions, suggests it contributes to recurrence of disease after treatment withdrawal.
A single-cell transcriptional gradient in human cutaneous memory T cells restricts Th17/Tc17 identity

Christopher P. Cook,1,2,14 Mark Taylor,1,3,14 Yale Liu,2,4,14 Ralf Schmidt,5 Andrew Sedgewick,6 Esther Kim,7 Ashley Hailer,1 Jeffrey P. North,1 Paymann Harirchian,1,2 Hao Wang,8 Sakeen W. Kashem,1,2 Yanhong Shou,9 Timothy C. McAlmont,1,10,11 Stephen C. Benz,7 Jaehyuk Choi,12 Elizabeth Purdom,8 Alexander Marson,5 Silvia B.V. Ramos,13 Jeffrey B. Cheng,1,2,15,* and Raymond J. Cho1,15,16,*

1Department of Dermatology, University of California, San Francisco, San Francisco, CA, USA
2Dermatology, Veterans Affairs Medical Center, San Francisco, CA, USA
3Clinical Research Centre, Medical University of Białystok, Białystok, Poland
4Department of Dermatology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, ShaanXi 710004, P.R. China
5Gladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA
6NantHealth, Inc, El Segundo, CA, USA
7Division of Plastic Surgery, University of California, San Francisco, San Francisco, CA, USA
8Department of Statistics, University of California, Berkeley, Berkeley, CA, USA
9Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, P.R. China
10Department of Pathology, University of California, San Francisco, San Francisco, CA, USA
11Golden State Dermatology Associates, Walnut Creek, CA, USA
12Department of Dermatology, Northwestern University, Evanston, IL, USA
13Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
14These authors contributed equally
15Senior author
16Lead contact
*Correspondence: Jeffrey.Cheng@ucsf.edu (J.B.C.), raymond.cho@ucsf.edu (R.J.C.)
https://doi.org/10.1016/j.xcrm.2022.100715

SUMMARY

The homeostatic mechanisms that fail to restrain chronic tissue inflammation in diseases, such as psoriasis vulgaris, remain incompletely understood. We profiled transcriptomes and epitopes of single psoriatic and normal skin-resident T cells, revealing a gradated transcriptional program of coordinately regulated inflammation-suppressive genes. This program, which is sharply suppressed in lesional skin, strikingly restricts Th17/Tc17 cytokine and other inflammatory mediators on the single-cell level. CRISPR-based deactivation of two core components of this inflammation-suppressive program, ZFP36L2 and ZFP36, replicates the interleukin-17A (IL-17A), granulocyte macrophage-colony-stimulating factor (GM-CSF), and interferon gamma (IFNγ) elevation in psoriatic memory T cells deficient in these transcripts, functionally validating their influence. Combinatoric expression analysis indicates the suppression of specific inflammatory mediators by individual program members. Finally, we find that therapeutic IL-23 blockade reduces Th17/Tc17 cell frequency in lesional skin but fails to normalize this inflammatory-suppressive program, suggesting how treated lesions may be primed for recurrence after withdrawal of treatment.

INTRODUCTION

Cytokine signaling drives common types of pathologic skin inflammation, such as the Th1 and Th17 populations causative for psoriasis vulgaris.1 Over the past 10 years, targeted inhibition of these pathways has generated effective, biologic therapies for diseases such as psoriasis and revealed skin-resident T cell populations that support recurrent disease.2 However, many mechanistic aspects of tissue inflammation remain unclear, particularly how pathogenic activation of these pathways is restrained between clinical flares. Nor is it certain how initial inflammatory activation amplifies within immune cell populations to produce symptomatic skin lesions.

The emergence of single-cell RNA sequencing (scRNA-seq) has made it possible to analyze cutaneous biological responses in ever higher resolution.3-6 These profiles can uniquely reveal inflammatory abnormalities in immune and stromal cells, providing a fine-grained portrait of how pathogenic changes reprogram complex tissues. However, these approaches have not yet closely examined how healthy, uninflamed T cells transition to a pathogenic state in chronic skin disease. In experimental settings outside of skin, T cell populations appear comprised of continuums of cellular identity, which robustly influence inflammatory activation.7 It is yet unknown if similar gradients operate in clinical disease and how they control pathogenic immunological behavior.
To investigate T cell identity and consequence in an in vivo setting, we scRNA-seq-profiled CD45+ immune cells isolated from lesional skin in eight patients with active cases of the prototypical Th17/Tc17 skin disease psoriasis vulgaris and compared them with seven uninflamed, normal controls. In addition to searching for molecular abnormalities distinguishing inflamed from normal cells, we sought to determine if such alterations correlated with each other in biologically specified programs. We also asked how pathogenic immune cell identities in psoriasis lesions, as revealed by scRNA-seq, might evolve during therapeutic treatment of interleukin-23 (IL-23) pathway overactivity.

RESULTS

scRNA-seq of T cells isolated from psoriatic lesions and uninflamed skin reveals both pathogenic Th17 and Tc17 activation and suppression of inflammation-suppressive genes

scRNA-seq using the 10x Genomics Chromium droplet-based methodology was performed in tandem with cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq; protein epitope) marker expression defining major T cell subpopulations (>5% of all T cells) from 8 psoriasis and 7 normal skin samples. We performed high-resolution unsupervised clustering on CD3+ cells and examined major classes that each represented more than 5% of all T cells in our samples (Table S3). We defined these six T cell classes passing this filter based on their transcriptional and epitope (CITE-seq) markers (Figure 1A), including central memory cells (Tcms), two tissue-resident memory (Trm1 and Trm2) populations, one exhausted and one activated cytotoxic CD8+ T lymphocyte population (CTLex and CTLac, respectively), and regulatory T cells (Tregs). Tcms were CD45RA+/C0+CD62L+/CCR7+, while the two closely related Trm classes were CD69+(epitope)/CD103+, distinguished from each other by only a small set of non-canonical markers (Table S3). Relative to CTLac, CTLex harbored elevated PDCD1, LAG3, and PRF1. All six classes were of transcriptomes and epitopes by sequencing (CITE-seq; see STAR Methods) on CD45+ immune cells isolated from lesional skin biopsies of 8 patients with psoriasis, comparable in cohort size to recent scRNA-seq studies (Tables S1 and S2). Cutaneous CD45+ cells were also isolated and profiled from seven uninflamed donors. We performed high-resolution unsupervised clustering on CD3+ cells and examined major classes that each represented more than 5% of all T cells in our samples (Table S3). We defined these six T cell classes passing this filter based on their transcriptional and epitope (CITE-seq) markers (Figure 1A), including central memory cells (Tcms), two tissue-resident memory (Trm1 and Trm2) populations, one exhausted and one activated cytotoxic CD8+ T lymphocyte population (CTLex and CTLac, respectively), and regulatory T cells (Tregs). Tcms were CD45RA+(epitope)/CD62L+/CCR7+, while the two closely related Trm classes were CD69+(epitope)/CD103+ and also CXCR6+11, distinguished from each other by only a small set of non-canonical markers (Table S3). Relative to CTLac, CTLex harbored elevated PDCD1, LAG3, and PRF1. All six classes were
robustly represented in each of our 15 patient samples and in aggregate ranged from 62% to 81% of T cells in each sample (Figure 1B; Table S3; Figure S1).

We next examined differential gene expression in T cell subpopulations in the 8 psoriasis samples against our 7 uninfamed, normal controls using a pseudo-bulk approach. Elevation in psoriatic T cells of Th17/Tc17 cytokines such as IL17A, IL17F, IL26, IFNG, and CXCL13 occurred predominantly in a population harboring skin-resident memory T cells markers (Trm1; Figure 1C; Table S4). IL22 expression was lower and thus less reliable for bulk comparison in these data. A broad array of T cell activation markers such as CTLA4, CD2, and CD82 were also elevated in these single cells expressing psoriatic cytokines, as was suppression of a series of inflammation-suppressive transcripts not previously reported as a major feature of T cells in psoriasis or other inflammatory skin diseases. Such transcripts include ZFP36L2 and ZFP36, two tristetraprolin family members previously shown to be capable of repressing inflammatory potential in murine and human T and B cells. In fact, among the 140 transcripts repressed >1.5 average log2 fold change (FC) in the Th17/Tc17 cytokine-expressing Trm1 cell class with an adjusted p-value <0.01, we also observed multiple other genes known to suppress inflammatory cellular identity, including inhibitors of JAK/STAT (SOCS1 and SOCS3) and Th17 signaling (CD69), negative regulators of CD8+ cytotoxic function (LGALS1), and promoters of Treg activity (CCL22). Downregulation of these inflammation-suppressive genes was also observed in psoriatic samples in other T cell classes, most strongly Tcm and Trm2 (Table S4), although T cells expressing canonical psoriatic cytokines classified primarily in the Trm1 category.

Because Th17 and Tc17 cells have each been reported as arising from skin-resident memory cells, we were curious if both populations could be identified in our skin-resident memory T cells, which harbored virtually all expression of psoriatic cytokines. Psoriatic T cells in the Trm1 subpopulation were subclassified as CD4+ and CD8+ based on expression of CD4, CD8A, or CD8B (STAR Methods; Table S3) as in other recent studies. As seen in Figure 1D, both the psoriatic CD4+ and CD8+ subpopulations substantively expressed IL17A, IL17F, IL26, and IFNG; we hereafter refer to these classes as Th17 and Tc17, respectively.

A ZFP36L2-centric cell identity gradient defines pathogenic cytokine and inflammatory transcript expression in psoriatic skin-resident memory T cells on the single-cell level

The detection of these transcriptional differences allowed us to evaluate two differing hypotheses regarding T cell identity in psoriasis. First, upregulation of psoriatic inflammatory transcripts and downregulation of inflammation-suppressive individual gene transcripts might simply occur in an unrelated pattern within Th17/Tc17 single cells. Alternatively, expression of these two gene sets might be coordinately linked in specific, related patterns on the single-cell level. To distinguish these possibilities, we examined correlations between IL17A and IL17F and other highly expressed transcripts in skin-resident memory T cells. To eliminate artifacts, gene values were batch corrected at the sample level using the CPCA method in the R package iCellR (STAR Methods). Intriguingly, not only was expression of IL17A and IL17F each highly correlated with one another, and also with IFNG, but the greatest levels of anti-correlation were observed against many of the inflammation-suppressive transcripts we described above as downregulated in this class. In fact, by this measure, ZFP36L2 was the single most anti-correlated transcript out of 16,348 assessed genes versus both IL17A (β = −0.58, p < 2 × 10−5) and IL17F (β = −0.65, p < 2 × 10−5) expression in Th17/Tc17 cells (Figures 2A and S2). A similar, high degree of anti-correlation was also observed between psoriatic cytokine transcripts and ZFP36, whose expression closely tracks that of ZFP36L2 in single T cells (Table S5).

We asked if pro-inflammatory transcripts beyond IL17A and IL17F were elevated in single memory T cells with the lowest ZFP36L2 magnitude. Indeed, transcripts demonstrating Spearman anti-correlation against ZFP36L2 of p < −0.6 (p < 2.1 × 10−344, 43/16,343 assessed genes) included the psoriasis-related cytokine IL26 and the T cell activation modulator CD2, as well as multiple T cell receptor components (CD3D and CD3G) and activation markers (CD81, CD82, and CD96) (Figure 2A; Table S5). Other psoriasis-related genes also enriched in the most ZFP36L2-deficient cells included the effector chemokine CXCL13 (p = −0.49, p < 5.9 × 10−305).

The correlation graphs in Figure 2B show that ZFP36L2 and inflammatory transcript expression opposed each other in single Th17/Tc17 cells as a continuous gradient rather than, for example, in discrete classes. This gradient was relatively muted in uninfamed Trms and most evident in the transition from Trms in healthy, uninflamed tissue to Th17/Tc17 cells in lesional psoriatic skin. This phenomenon presented visually as the blue, normal T cells observed at the upper left end of each gradient (with high ZFP36L2 expression and low cytokine expression), in contrast to the dark red lesional T cells extending toward the lower right. Substantial expression of key Th17 cytokines such as IL17A, IL17F, and IL26 was restricted sharply to psoriatic single Th17/Tc17 cells whose ZFP36L2 level was suppressed below that of Trms in normal, uninflamed skin.

It was not clear whether such gradient patterns arose primarily out of either the Th17 or Tc17 subpopulations. We therefore repeated this analysis after compartmentalizing CD4+ and CD8+ subpopulations as described above. As illustrated in Figure S3, the gradients involving ZFP36L2 were robustly detected in both subpopulations, confirming a recurrent patterning of pathogenic cytokines within both Th17 and Tc17 identities. Thus ZFP36L2 deficiency, paralleled by depressed ZFP36 levels, appears to specify a pathogenic inflammatory state in psoriatic T cells, a transcriptional identity largely absent in the corresponding resident-memory T cells isolated from non-inflamed skin (Figure 2B, blue data points).

The prominent anti-correlation between tristetraprolin family members and Th17/Tc17 cytokines also led us to evaluate their relationship beyond human skin T cells. In mice, thymically derived murine γδ T cells produce IL17 isoforms and drive psoriasiform inflammation. These γδ T cells express cognate Trm markers, proliferate in situ in response to local...
tissue cytokines, and do not freely recirculate out of the skin and are thus frequently regarded as skin-resident analogs in psoriasis models. In re-analyzing single-cell data from imiquimod-provoked gd T cells in mice, we again observed a steep anti-correlation between levels of Zfp36l2 and the Th17/Tc17 cytokines Il17a, Il17f, and Il22 (Figure 2C). In data from stimulated human peripheral T cells, we also found that Il17f was expressed almost exclusively in low Zfp36l2-expressing single cells (Figure S4), indicating that this relationship extends to psoriatic cytokine expression outside of tissue-resident settings.

While we primarily detected and modeled significant psoriatic cytokine expression in cells falling in the Trm1 subpopulation, anti-correlation of other inflammatory markers against Zfp36l2/Zip36 levels was also observed in our Tcm, Treg, and CD8+ classes (Figure 2D; Table S5), suggesting that tristetraprolin family member expression pervasively defines inflammatory cell identity across skin T cell classes.

Figure 2. scRNA-seq identifies ZFP36L2 as the transcript most anti-correlated with psoriatic inflammatory gene expression in skin-resident T cells

(A) Positive correlation of IL17A expression in single Trm/Th17/Tc17 cells with expression of pro-inflammatory transcripts and cytokines (right half of graph, labeled in red). Deficiency in IL17A-expressing single T cells of inflammation-suppressive genes such as ZFP36L2, ZFP36, and BTG1 is shown as negative Spearman correlations (left half of graph, labeled in blue). Data from 8 psoriasis and 7 normal samples. An analogous correlation graph for IL17F is shown in Figure S2.

(B) ZFP36L2 suppression predicts induction of numerous other pro-inflammatory mediator transcripts from Th17/Tc17 in lesional psoriatic skin from this study (red, all 8 samples pooled) versus healthy controls (blue, all 7 samples pooled). The y axis shows ZFP36L2 expression, the x axis shows imputed cytokine transcript levels, and each point represents a single T cell.

(C) scRNA-seq from prior studies of CD45+ cutaneous immune cells isolated from imiquimod-provoked (red, 3 samples pooled) versus control treated mice (blue, 3 samples pooled) show maximal expression of IL17A, IL17F, and IL22 with highest ZFP36L2 suppression. The y axis shows ZFP36L2 expression, the x axis shows imputed cytokine transcript levels, and each point represents a single γδ T cell. For both axes, the standard imputed expression value (iCellR) has been normalized and log-transformed (Seurat; STAR Methods).

(D) Relationship between ZFP36L2 loss and inflammatory mediator expression seen in all major skin T cell classes but strongest in skin-resident memory T cells.
ZFP36L2 or ZFP36 knockout in primary CD4+ and CD8+ T cells elevates protein and transcript expression of 3′ ARE-containing cytokines

We were curious if marked suppression of ZFP36L2 and ZFP36 mRNA abundance simply correlated with increased expression of key cytokines or, instead, functionally elevated their levels. Both ZFP36L2 and ZFP36 bind AU-rich elements (AREs) in the 3′ untranslated region (UTR) of mRNA transcripts, directly inhibiting ribosomal access and translation. Tristetraprolin family members have been shown to suppress ARE-harboring cytokine transcript levels in mouse T cell populations32 and in human Tregs.33 We utilized CRISPR-Cas9 ribonucleoprotein complexes to genetically disrupt both loci in primary peripheral T cells because of the technical challenges in obtaining human cutaneous T cells in sufficient numbers for these assays. As the relationship between ZFP36L2 and Th17/Tc17 cytokine production was broadly conserved in both tissue-resident and other skin T cell classes (Figures 2B and 2D), we targeted knockout to bulk CD4+ and CD8+ T cells. Two distinct guide RNAs (gRNAs) were designed for both ZFP36L2 and ZFP36; greater than 81% allele knockout was confirmed for each gRNA, using both Sanger-based (Synperformed using an additional donor (Figure S5). A negative control gRNA for the human AAVS1 safe-harbor-targeting and non-targeting negative control gRNAs. *p < 0.05, **p < 0.01, ***p < 0.001, Student’s two-sample, two-tailed t tests.

The observed cytokine induction under these conditions was substantial. ZFP36L2 knockout resulted in as much as a 1.6-fold increase in IFNγ-positive CD8+ T cells, from 29% to 47% (guide L2g2, p < 0.01; Figure 3A, second row). ZFP36L2 knockout also induced TNF-α and IL-17A expression (Figure 3B). GM-CSF was assayed specifically for the ZFP36 knockout, based on a previously reported regulatory relationship.36

The observed cytokine production limits for 10x Genomics 3′scRNA-seq analysis.4 As shown in Figure 3A, knockout of ZFP36L2 in both CD4+ and CD8+ T cells significantly induced interferon gamma (IFNγ), TNF-α, and IL-17A. By comparison, ZFP36 knockout induced IFNγ and TNF-α in both populations but did not appreciably affect IL-17A expression (Figure 3B). GM-CSF was assayed specifically for the ZFP36 knockout, based on a previously reported regulatory relationship.36

The binding of tristetraprolin family members to cytokine mRNA also targets them for deadenylation and degradation,37 we also assessed ZFP36L2 influence on transcript levels. We bulk RNA-seq-profiled CD4+ primary human T cells after ZFP36L2 disruption performed with three distinct donors (Table S7; STAR Methods). Applying the differential expression analysis package sleuth to these data,38 among transcripts for secreted cytokines, we detected that ZFP36L2 knockou significantly increased levels of IL17A and IFNG, which are elevated in ZFP36L2-deficient T cells (p < 0.01; Figure 2A). However, other pro-inflammatory genes elevated in ZFP36L2-deficient T cells but lacking 3′AREs, such as CXCL13 and CD82, were not induced by its disruption, suggesting that there are additional
mechanisms responsible for their upregulation. To further distinguish direct targets of tristetraprolin proteins in T cells, we examined data from a recent study employing a binding-based biochemical assay to identify Zfp36 binding partners in wild-type CD4+ cells.19 Of 382 transcripts showing high-magnitude suppression versus ZFP36 level in our study (r < 0.5, p < 0.01), 199 were also identified in this screen (Table S5).

ZFP36L2 defines programmatic attenuation of other inflammation-suppressive transcripts in rash lesional T cells
Our findings support a model in which repressed ZFP36L2 and ZFP36 expression, in psoriatic Th17/Tc17 cells, elevates the abundance of 3' ARE-containing cytokines. However, many other pro-inflammatory transcripts that were elevated in ZFP36L2/ZFP36-deficient T cells lack such 3' regulatory elements (e.g., CD2, CD82, and T cell receptor components), suggesting a different regulatory cause. We speculated that other inflammation-suppressive genes might be downregulated in concert with ZFP36L2 in single Th17/Tc17 cells, more broadly activating an inflammatory state. We thus examined the 50 transcripts most correlated with ZFP36L2 in Trms/Th17/Tc17 cells (p > 0.4, <0.2% of assessed transcripts, p < 6.1 x 10^-364, excluding ribosomal or mitochondrial transcripts; Table S5) for prior biological evidence of immune pathway restriction. Strikingly, many inflammation-suppressing genes that we noted earlier as downregulated in psoriatic T cells were found in this set, including ZFP36, SOCS1, SOCS3, CCL22, and CD69, as well as the global quiescence enforcers BTG140 and TXNIP40 (Figure 4A). We thus termed these genes, which appear coherently suppressed in the highest cytokine-expressing single Th17/Tc17 cells, the ZFP36L2 inflammation-suppressive transcriptional program, or ZIST.

ZFP36L2 correlates with other ZIST genes in both skin-resident CD4+ and CD8+ subfractions (Figure S3). However, its statistical correlation is weaker in the Treg subpopulation and CD8+ cells outside of the Trm1 cluster (Figure 4B). ZIST transcripts were not identified as significantly altered in T cells in a study of collagenase artifacts in human tissue processing.41

We hypothesized that the elevated expression of multiple inflammation-suppressive genes (i.e., ZIST) normally restricts T cell inflammatory tone. Exogenous stimulation then downregulates ZIST components, an effect observed for both ZFP36L2 and ZFP36 in peripheral T cells,7 potentiating inflammation.

Figure 4. Loss of a coordinated inflammation-suppressive program centered on ZFP36L2 defines inflamed psoriatic skin-resident memory cells
(A) ZFP36L2 expression coordinates with that of numerous other global inflammatory suppressors in Th17/Tc17 single cells in lesional psoriatic skin (red, all 8 samples pooled) compared with healthy controls (blue, all 7 samples pooled), a program we term the ZFP36L2 inflammation suppressive transcript program (ZIST). The y axis shows ZFP36L2 expression, the x axis shows transcript levels for the specified suppressor gene, and each point represents a single T cell.
(B) Correlation between most ZIST genes is statistically significant in different T cell subclasses but is strongest in Trm1.
(C) Combinatoric analysis shows top six ZIST gene groups whose combined downregulation best predicts individual inflammatory transcript expression (Spearman correlation coefficient displayed at right for gene named at left, different ZIST transcript subsets denoted by filled red circles in each row), revealing predictive associations of ZFP36L2 for IL17A, as well as of BTG1 for CD82.
While expression of ZIST members appears strongly correlated within Trms/Th17/Tc17 cells, we were curious if their individualistic effects on specific inflammatory targets might still be distinguishable on a single-cell level. Such associations would implicate individual ZIST members as regulators of distinct aspects of psoriatic T cell activation. To test this hypothesis, we implemented a single-cell, combinatoric approach to test correlations between (1) transcript levels of all possible, non-repeating sets of predictor (i.e., ZIST) genes and (2) expression of individual inflammatory mediator genes described above.

By testing all possible ZIST sets in their prediction of inflammatory transcript expression, this approach is capable of testing correlative effects of groups of genes but also quantitatively discerning if components of sets have outsize effects on targets. Briefly, the batch-corrected matrices described above were passed to Monocle3, and all possible combinations of predictor (ZIST) genes were then summed using the aggregate gene function, in order to calculate Spearman rank correlation with respect to inflammatory mediator target genes (Table S8; STAR Methods).

These analyses reveal two intriguing features of psoriatic inflammatory activation in resident T cell populations. First, while downregulated ZFP36L2 and ZFP36 rank as the best individual predictors of inflammatory gene expression, combinations of suppressed ZIST program genes consistently perform even more strongly (Figure 4C; Table S5). Therefore, we hypothesize that a yet unidentified global regulator coordinately suppresses these ZIST program genes, producing a single, major inflammatory gradient in T cells from psoriatic skin. Secondly, even within this dominant axis, our combinatorial analysis can still distinguish gene-specific patterns. For example, ZFP36L2 suppression is more predictive than that of ZFP36 for IL17A (p = −0.513 versus −0.416) and IL17F (p = −0.625 versus −0.486) expression. In contrast, combined ZFP36L2 and ZFP36 suppression better predict expression of IFNG (p = −0.481 versus −0.418) and CXCL13 (−0.578 versus −0.490) than ZFP36L2 alone.

Notably, these findings reflect our CRISPR-based experimental data that ZFP36L2, but not ZFP36, represses IL-17A in human CD4+ and CD8+ T cells, while both suppress IFN-γ (Figure 3). Figure 4D also shows an influence of BTG1 suppression on CD82 expression not observed for cytokine targets; this prediction agrees with the experimental induction of CD82 by BTG1 knockout, suggesting that our model may predict specific regulatory relationships for additional validation. While these analyses are intended for examination of broad trends rather than ascribing significance to each individual ZIST combination, we also implemented a stepwise model comparison algorithm using R/cocor, establishing significance between combinatoric pairs (STAR Methods; Table S8).

**ZIST program expression defines a trajectory reflecting an inherent molecular gradient from normal to psoriatic skin-resident memory cells**

Given the coherence of the ZIST program in Th17/Tc17 single cells, we thought that its magnitude might reveal an inherent trajectory defining molecular evolution from normal to inflamed T cells in psoriasis. To examine such a natural trajectory, we referred to as a pseudotime, we optimized a manifold consistent of Trms/Th17/Tc17 cells from all 15 samples and overlaid expression of key transcript sets. Briefly, we calculated an integrated expression value for each gene program within each cell, representing the summed standardized values of each constituent gene within a set. The cells were then organized in two-dimensional space based on a rooted trajectory.

After batch correction, this trajectory shows evenly distributed contributions from all our samples (Figure 5A), and unsurprisingly, its rooted, unsupervised gradient is defined by a transition from normal Trms to psoriatic Th17/Tc17 cells (Figure 5B). This trajectory is not strongly biased by either CD4/CD8 expression (Figure 5C), nor is it a product of central memory markers such as CCR7 or SEL (Figure 5D). As we speculated, the major transition from normal to pathologic T cells is strongly anti-correlated with ZIST program magnitude (Figure 5E) and is correlated with cytokine and inflammatory mediator expression (Figures 5F and 5G), a phenomenon that is robustly represented on the individual-sample level (Figure 5G). The rooted trajectory is notable for its linear nature, with few outlying developmental sinks (Figure 5H). This analysis thus reinforces a model in which psoriatic skin-resident T cells harbor an inflammatory identity inversely related to expression of ZIST program members.

**Therapeutic IL-23 blockade drastically reduces Th17/ Tc17 cell frequency, but residual Trms in healed psoriasis lesions show persistent ZIST program suppression**

We next sought to understand how treatment of psoriasis using IL-23 blockade would affect our inflammation-suppressive gradient. Although IL17A and IL17F cytokine expression should be largely quenched by IL-23 blockade, the pro-inflammatory identity represented by ZIST suppression might persist in residual T cells. To assess this hypothesis, we isolated and performed scRNA-seq on lesional T cells from three patients with psoriasis prior to initiation on the IL-23-blocker tildrakizumab. After at least 8 weeks of biologic treatment, which produced a 75% or greater reduction in psoriasis area and severity index score in all three patients, we re-biopsied and profiled clinically resolved skin adjacent to the original sample sites for comparison. Tildrakizumab dramatically reduces Th17/Tc17 cells in psoriatic lesions, an expected feature of blocking IL-23 signaling to skin-resident memory cells, both in absolute number (Figure 6A) and, importantly, as a relative percentage of T cell class (Table S9). However, in residual resident memory T cells of the Trm1 class isolated from clinically resolved psoriasis lesions, our scRNA-seq analysis also shows persistent abnormal suppression of ZIST elements, with mid-treatment versus normal comparison Kruskal-Wallis p values <2 × 10−16 for all transcripts (Figure 6B; patient-level data in Table S9). Plotting ZIST program member expression against ZFP36L2 levels in Trms/Th17/Tc17 cells from these pre- and mid-treatment psoriasis lesions shows that despite resolution of visible inflammatory plaques, the overall inflammatory-suppressive gradient in T cells remains sharply suppressed (Figure 6C). Some, but not all, inflammatory transcripts lacking AREs also appear persistently elevated in the context of clinical improvement, including CD2 and CD3G (Table S9). These data thus reveal that skin-resident memory cells under IL-23 blockade continue to harbor a molecularly primed state closely resembling that in inflamed skin. Such
pro-inflammatory abnormalities in cell identity nominate a mechanism by which psoriatic lesions may rapidly recur after withdrawal of treatment.

**DISCUSSION**

Th17/Tc17 cytokines are well-established to play a central, therapeutically actionable role in the development of psoriasis, but these pathways only partly explain the clinical course of skin inflammatory disease. Dynamic, secondary mechanisms likely activate immune cell populations during cutaneous flares, which are rapid and unpredictable. Our analysis of single-cell sequencing data from psoriasis lesions reveals a reactive layer of heterogeneity embedded in cutaneous T cells. Specifically, a transcriptional single-cell identity involving multiple inflammation-suppressive regulators (described here as the ZIST program) appears to play a dominant role in defining the most pathogenically activated psoriatic T cells.

Some ZIST members outside of ZFP36L2 and ZFP36 post-transcriptionally suppress pre-formed Th17/Tc17 cytokine transcripts and are known to be rapidly de-activated, nominating a mechanism by which chronic rashes might rapidly flare. Like the numerous genes that are upregulated in and augment the inflammatory capacity of inflamed immune cells, the exact delineation of such a program is partially arbitrary and likely to be substantially tissue specific. Our findings reveal that ZIST inflammation-suppressive transcripts exist in a single-cell continuum. This gradient is then coordinately shifted downward in psoriatic lesions, relieving suppression of inflammation and driving cytokine expression in the most ZIST-depressed subpopulation. In fact, we find that IL17F and IL26 expression emerges only in those psoriatic T cells whose ZIST expression is depressed below the range observed in normal control samples (Figure 2B), underscoring the tight link between this gradient and pathogenic inflammation.

We investigate this regulatory pattern primarily in our Trm1 subpopulation, in which Th17/Tc17 cytokines are expressed in psoriasis samples and can be studied directly, but other inflammatory markers negatively correlate with ZFP36L2-deficiency in other T cell classes (Figure 2D). A recent study also observed ZFP36L2 suppression in stimulated Tregs, as seen in our data, apparently elevating Treg tone and perhaps representing a feedback mechanism that is overwhelmed in the context of pathogenic inflammation.

We propose that in psoriatic lesion development, general, exogenous inflammatory insults suppress elements of the ZIST program in healthy Trms, leading to enhanced pathogenic psoriatic cytokine and inflammatory mediator transcript levels. An
increasing inflammatory milieu then further depresses ZIST levels, as previously shown with in vitro suppression of ZFP36L2 and ZFP36 in peripheral T cells by T cell receptor (TCR) stimulation.7,33 Our pre- and mid-tildrakizumab treatment data support this model, in which IL-23 signaling and ZIST regulation represent dual, distinguishable inputs, as IL-23 blockade sharply reduces Th17/Tc17 cell density but does not normalize ZIST suppression in Trms from healed psoriatic lesions.

Although our patients represent a limited initial cohort that must be expanded, such a molecularly primed, inflammatory cell identity persisting despite IL-23 blockade might accelerate recurrence of psoriatic lesions after withdrawal of treatment. ZFP36L2 and ZFP36 attenuation help explain cytokine induction in ZIST-deficient T cells but are unlikely to directly elevate the numerous other pro-inflammatory transcripts lacking 3' ARE sequences, their binding target. Such inflammatory markers include CD2, CD3G, and CD82, which are known to establish the T cell immunological synapse and maintain signaling downstream of the TCR,36 and their upregulation is likely to further activate more greatly ZIST-deficient single T cells. Potential sources for regulation of these other inflammatory markers include ZIST members such as BTG1, whose suppression tracks specifically with CD82 elevation (Figure 4D) and which is not affected by ZFP36L2/ZFP36 knockdown (Table S7), a relationship that has been mechanistically validated in murine T cells.39 Therefore, the combinatoric model we present here may be used to predict and further experimentally validate other suppressor-inflammatory mediator relationships.

The persistence of ZIST gradient abnormalities in psoriasis despite IL-23 blockade nominates this regulatory mechanism as an intriguing, complementary therapeutic target in overactivity of the Th17/Tc17 axis, as does recent work indicating that fibroblasts may also suppress psoriatic inflammation through ZFP36L2.47 It also remains to be understood whether this transcriptional gradient acts similarly on Th2 cytokines in atopic dermatitis or in other chronic skin inflammatory disorders. One key technical limitation of our study is the inability to enhance activity of ZFP36L2 or other ZIST elements in human skin. The tightly linked expression of ZIST program elements strongly suggests that a yet undiscovered global regulator produces this gradient cell identity, analogous to factors such as FOXO1 and KLF2 that guide the transition from naive to memory cells. A means to selectively activate ZFP36L2 and other ZIST genes in human T cells remains an important milestone for future work.
Limitations of the study
This study is limited by the relatively small number of samples analyzed, given the current costs and technical challenges of scRNA-seq. It is also not possible to formally exclude influences of tissue dissociation on the skin-resident T cell transcriptional profiles we report here. Finally, we lack the technical capability to directly genetically modify T cells isolated from human skin, limiting direct, in vitro validation of the inflammation suppression function of our candidates. These technical bounds in genetic manipulation also restrict our capacity to measure the aggregate impact of downregulation of multiple inflammation-suppressive transcripts in our T cell gradients.

STAR METHODS
Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Patient characteristics
- METHOD DETAILS
  - Skin sample collection, single cell RNA-seq, and CITE-seq processing
  - Single cell RNA sequencing data processing
  - Dimensional reduction and unsupervised clustering
  - scRNA-seq correlation analysis
  - Tmm1 manifold and developmental trajectory inference
  - Combinatorial single-cell inflammatory mediator prediction analysis
  - Preparation of CRISPR/CAS9 Ribonucleoprotein particles
  - Donor T cell nucleofection
  - PCR-based validation of CRISPR-based T cell gene knockout
  - Intracellular cytokine assays of CRISPR-modified T cells
  - mRNA isolation and bulk RNA-seq of CRISPR-modified CD4+ T cells
  - Bulk RNA-seq analysis
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - Statistical analysis for flow cytometry data
  - Statistical analysis for scRNA-seq and bulk RNA-seq data

SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.xcrm.2022.100715.

ACKNOWLEDGMENTS
We wish to thank Rachel Sevey for help with figure illustration and Bahram Ra- zani, MD, PhD, for a critical reading of the manuscript. R.J.C. and J.B.C. are supported by a LEO Foundation grant, Sun Pharmaceuticals, and Sanofi.

J.B.C. is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health K08AR067243 and the National Psoriasis Foundation. A.M. holds a Lloyd J. Old STAR award from the Cancer Research Institute, was an investigator at the Chan Zuckerberg Biohub, held a Career Award for Medical Scientists from the Burroughs Wellcome Fund, and has received funds from Parker Institute for Cancer Immunotherapy and the Innovative Genomics Institute. The Marson lab has received research support from Juno Therapeutics, Epinomics, Sanofi, GlaxoSmithKline, Gilead, and Anthem.

AUTHOR CONTRIBUTIONS
C.P.C., Y.L., J.B.C., and R.J.C. designed the study. E.K., J.B.C., and R.J.C. supervised sample collection and processing. C.P.C., Y.L., P.H., and R.S. performed sample preparation and analysis. C.P.C., Y.L., M.T., A.S., E.P., H.W., Y.S., J.C., and S.B.V.R. performed computational analysis. J.P.N. performed histopathology. C.P.C., Y.L., J.B.C., and R.J.C. wrote the manuscript with contributions from R.S., A.M., M.T., E.P., H.W., A.S., E.K., J.P.N., P.H., S.W.K., S.C.B., and S.B.V.R.

DECLARATION OF INTERESTS
A.M. is a cofounder of Arsenal Biosciences, Spotlight Therapeutics, and Survey Genomics. A.M. serves on the boards of directors at Spotlight Therapeutics and Survey Genomics and is board observer (and former member of the board of directors) at Arsenal Biosciences. A.M. is a member of the scientific advisory boards of Arsenal Biosciences, Spotlight Therapeutics, Survey Genomics, and NewLimit. A.M. owns stock in Arsenal Biosciences, Spotlight Therapeutics, NewLimit, Survey Genomics, PACT Pharma, and Merck. A.M. has received fees from Arsenal Biosciences, Spotlight Therapeutics, NewLimit, 23andMe, PACT Pharma, Juno Therapeutics, Trizell, Vertex, Merck, Amgen, Genentech, AlphaSights, Rupert Case Management, Bernstein, and ALDA. A.M. is an investor in and informal advisor to Offline Ventures and a client of EPIQ.

INCLUSION AND DIVERSITY
We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. One or more of the authors of this paper self-identifies as an under-represented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community. One or more of the authors of this paper received support from a program designed to increase minority representation in science. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list. The author list of this paper includes contributors from the location where the research was conducted who participated in the data collection, design, analysis, and/or interpretation of the work.

Received: January 4, 2022
Revised: May 21, 2022
Accepted: July 14, 2022
Published: August 16, 2022

REFERENCES
1. Lowes, M.A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L.C., Haider, A.S., Bowman, E.P., and Krueger, J.G. (2008). Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J. Invest. Dermatol. 128, 1207–1211.
2. Cheuk, S., Wikén, M., Blomqvist, L., Nylen, S., Talme, T., Ståhlé, M., and Eidslø, L. (2014). Epidermal Th22 and Th17 cells form a Localized disease memory in clinically healed psoriasis. J. Immunol. 192, 3111–3120.
3. Liu, Y., Wang, H., Taylor, M., Cook, C., Martínez-Berdeja, A., North, J.P., Hairichian, P., Hailer, A.A., Zhao, Z., Ghadiali, R., et al. (2022).
37. Rappol, P., Brune, B., and Schmid, T. (2021). Role of tristetraprolin in the resolution of inflammation. Biology 10, 66.
38. Yi, L., Pimentel, H., Bray, N.L., and Pachter, L. (2018). Gene-level differential analysis at transcript-level resolution. Genome Biol. 19, 53.
39. Hwang, S.S., Lim, J., Yu, Z., Kong, P., Sefik, E., Xu, H., Harman, C.C.D., Kim, L.K., Lee, G.R., Li, H.-B., and Flavell, R.A. (2020). mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science 367, 1255–1260.
40. Muri, J., Thut, H., and Kopf, M. (2021). The thioredoxin-1 inhibitor Txnip restraining effecter T-cell and germinal center B-cell expansion. Eur. J. Immunol. 51, 115–124.
41. O’Flanagan, C.H., Campbell, K.R., Zhang, A.W., Kabeer, F., Lim, J.L.P., Biele, J., Eirew, P., Lai, D., McPherson, A., Kong, E., et al. (2019). Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses. Genome Biol. 20, 210.
42. Noguchi, A., Adachi, S., Yokota, N., Hatta, T., Natsume, T., and Kawahara, H. (2018). ZFP36L2 is a cell cycle-regulated CCCH protein necessary for DNA lesion-induced S-phase arrest. Biol. Open 7, bio031575.
43. Brooks, S.A., Connolly, J.E., and Rigby, W.F.C. (2004). The role of mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science 305, 1554–1555.
44. Liau, N.P.D., Laktyushin, A., Lucet, I.S., Murphy, J.M., Yao, S., Whitlock, E., Callaghan, K., Nicola, N.A., Kershaw, N.J., and Babon, J.J. (2018). mRNA destabilization by mediating T cell polarization and immunological synapse formation. J. Immunol. 198, 1333.
45. Kim, S.H., Park, A., Yu, J., Kim, J., Song, H.-S., Bae, J., Chae, S.Y., Kim, S., Jung, W., and Kim, Y.-M. (2021). CD82 promotes CD8+ T cell immune responses by reducing membrane expression of MHC molecules and CD80. J. Immunol. 196, 1888–1902.
46. Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M.N., and Sergushichev, A. (2021). Fast gene set enrichment analysis. Preprint at bioRxiv. https://doi.org/10.1101/060012.
47. Kühnemuth, B., Piseddu, I., Knott, M., Vetter, V., Layritz, P., Endres, S., and Anz, D. (2017). CCL22 impedes T cell activation capacities of dendritic cells by reducing membrane expression of MHC molecules and CD80. J. Immunol. 198, 1333.
48. Angiolilli, C., Leijten, E.F.A., Bekker, C.P.J., Eeftink, E., Giovannone, B., Nordkamp, M.O., van der Wal, M., Thijs, J.L., Vastert, S.J., van Wijk, F., et al. (2022). ZFP36 family members regulate the Proinflammatory features of psoriatic dermal fibroblasts. J. Invest. Dermatol. 142, 402–413.
49. Korsunsky, I., Millard, N., Fan, J., Słowiński, K., Zhang, F., Wei, K., Bagienko, Y., Brenner, M., Loh, P.-R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods 16, 1289–1296.
50. Traag, V.A., Waltman, L., and van Eck, N.J. (2019). From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 9, 5233.
51. Saeiens, W., Cannoott, R., Todorov, H., and Saeys, Y. (2019). A comparison of single-cell trajectory inference methods. Nat. Biotechnol. 37, 547–554.
52. Qiu, P. (2020). Embracing the dropouts in single-cell RNA-seq analysis. Nat. Commun. 11, 1169.
53. Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D.M., Hill, A.J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F.J., et al. (2019). The single-cell transcriptional landscape of mammalian organogenesis. Nature 566, 496–502.
54. Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lenin, N.J., Livak, K.J., Mikkelson, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386.
55. Hittner, J.B., May, K., and Silver, N.C. (2003). A Monte Carlo evaluation of tests for comparing dependent correlations. J. Gen. Psychol. 130, 149–168.
56. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525–527.
57. Pimentel, H., Bray, N.L., Puente, S., Melsted, P., and Pachter, L. (2017). Differential analysis of RNA-seq incorporating quantification uncertainty. Nat. Methods 14, 687–690.
## STAR★METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Antibodies**      |        |            |
| PE anti-Human CD4   | BioLegend #317410 | Clone OKT4 |
| BV711 anti-Human CD8α | BioLegend #301044 | Clone RPA-T8 |
| APC anti-Human IFNγ | BioLegend #502512 | Clone 4S.B3 |
| FITC anti-Human TNFα | BioLegend #502906 | Clone MAb11 |
| PerCP/Cy5.5 anti-Human IL-2 | BioLegend #500322 | Clone MQ1-17H12 |
| TotalSeq-A anti-Human CD11c | BioLegend #371519 | Clone S-HCL-3 |
| TotalSeq-A anti-Human CD123 | BioLegend #306037 | Clone 6H6 |
| TotalSeq-A anti-Human CD127 | BioLegend #351352 | Clone A019D5 |
| TotalSeq-A anti-Human CD14 | BioLegend #367131 | Clone 6D3 |
| TotalSeq-A anti-Human CD141 | BioLegend #344121 | Clone M80 |
| TotalSeq-A anti-Human CD161 | BioLegend #339945 | Clone HP-3G10 |
| TotalSeq-A anti-Human CD19 | BioLegend #302259 | Clone HIB19 |
| TotalSeq-A anti-Human CD195 | BioLegend #359135 | Clone J418F1 |
| TotalSeq-A anti-Human CD196 (CCR6) | BioLegend #353437 | Clone G034E3 |
| TotalSeq-A anti-Human CD197 (CCR7) | BioLegend #353247 | Clone G043H7 |
| TotalSeq-A anti-Human CD1c | BioLegend #331539 | Clone L161 |
| TotalSeq-A anti-Human CD21 | BioLegend #354915 | Clone Bu32 |
| TotalSeq-A anti-Human CD207 (Langerin) | BioLegend #352207 | Clone 10E2 |
| TotalSeq-A anti-Human CD25 | BioLegend #302643 | Clone BC96 |
| TotalSeq-A anti-Human CD294 | BioLegend #350127 | Clone BM16 |
| TotalSeq-A anti-Human CD3 | BioLegend #300475 | Clone UCHT1 |
| TotalSeq-A anti-Human CD4 | BioLegend #344649 | Clone SK3 |
| TotalSeq-A anti-Human CD45RA | BioLegend #304157 | Clone HI100 |
| TotalSeq-A anti-Human CD45RO | BioLegend #304255 | Clone UCHL1 |
| TotalSeq-A anti-Human CD56 (NCAM) | BioLegend #362557 | Clone 5.1H11 |
| TotalSeq-A anti-Human CD69 | BioLegend #310947 | Clone FN50 |
| TotalSeq-A anti-Human CD8 | BioLegend #344751 | Clone SK1 |
| TotalSeq-A anti-Human CD80 | BioLegend #305239 | Clone 2D10 |
| TotalSeq-A anti-Human HLA-DR | BioLegend #307659 | Clone L234 |
| **Biological samples** | | |
| Human Peripheral Blood Leukopak, Fresh | | Cat# 200-0092 |
| **Chemicals, peptides, and recombinant proteins** | | |
| Recombinant Human IL-2 | PeproTech | Cat# 200-02 |
| X-VIVO 15 Serum-free Hematopoietic Cell Medium | Lonza | Cat# BE02-060Q |
| FBS | UCSF Cell Culture Facility | Cat# CCFAL008 |
| DAPI | Life Technologies | Cat# A20502 |
| Recombinant Cas9-NLS | UC Berkeley QB3 MacroLab | No Cat# |
| Dynabeads Human T-Activator CD3/CD28 | ThermoFisher Scientific | Cat# 11132D |
| PBS | UCSF Cell Culture Facility | Cat# CCFAL003 |
| β-Mercaptoethanol | ThermoFisher Scientific | Cat# 21985023 |
| RPMI-1640 | UCSF Cell Culture Facility | Cat# CCFAE001 |
| DNase I | Sigma | Cat# 10104159001 |
| Collagenase IV | Worthington Biochemical Corp. | Cat# LS004188 |

(Continued on next page)
**RESOURCE AVAILABILITY**

**Lead contact**
Correspondence and request for materials should be addressed to the lead contact for resources, Dr. Jeffrey B. Cheng (Jeffrey.Cheng@ucsf.edu).

**Materials availability**
This study did not generate new unique reagents.
**Data and code availability**
- Sequence data is submitted at the European Genome-Phenome Archive (EGA), which is hosted by the EBI and the CRG, under accession number EGA: S0001055271. Flow cytometry data reported in this paper will be shared by the lead contact upon request.
- All analysis scripts are available at the online repository https://github.com/cpcook1/TTP. All statistical analysis and plotting of scRNA-seq and cell surface protein data were performed using RStudio software (v1.2.5033).
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

**Patient characteristics**
Normal, healthy control skin obtained from patients undergoing mastectomies or reduction abdominoplasties and psoriasis lesional skin were obtained using protocols approved by the UCSF Human Research Protection Program Institutional Review Board. Informed consent was obtained from all patients donating samples based on these active protocols. Adult patients donating psoriasis samples from the trunk or proximal extremity were assessed at a Psoriasis Area Severity Index (PASI score) of 8 or more (moderate to severe disease). Histopathology was verified by a board-certified dermatopathologist. Patients undergoing IL23 blockade (tildrakizumab) treatment were enrolled under an IRB protocol as part of a study funded by Sun Pharma, had a pre-treatment PASI score of 7 or greater, and received at least two 100 mg treatments before mid-treatment biopsy of clinically resolved lesions at > 8 weeks. Comprehensive biographical metrics of all subjects from this study are available in Table S1.

**METHOD DETAILS**

**Skin sample collection, single cell RNA-seq, and CITE-seq processing**
Skin samples were obtained by 6 mm punch biopsy and minced into fine pieces using surgical scissors and transferred into 3 ml of RPMI-1640 medium supplemented with 10% fetal bovine serum, 100 IU/mL Penicillin+100 µg/mL Streptomycin, 10mM HEPES, collagenase type IV (200U/ml; Worthington) and 20 µg/ml DNase I (MilliporeSigma), then incubated for 16-18h at 37°C with 5% CO₂. After incubation, the suspension was filtered through a 100 µm cell strainer, pelleted by centrifugation at 1500 rpm for 5 min, and resuspended in 100 µL of FACS buffer (PBS supplemented with 2% FBS) containing APC conjugated human CD45 Antibody at a 1:33 dilution. After staining at 4°C for 30 min, cells were washed twice in FACS buffer, passed through a 45 µm filter and sorted for live CD45+ cells following the addition of DAPI at 1 µg/ml. For samples where CITE-seq was performed (Table S2), murine splenocytes were added to comprise 5% of total cells (to allow for computational adjustment for non-specific antibody binding). Blocking was performed with the addition of 5% Human TruStain FcX (Biolegend) in a 100 µL cell suspension volume for 10 minutes at 4°C, followed by CITE-seq antibody addition for 30 min at 4°C (TotalSeq-A antibodies, 0.5 ug for each antibody per 1 million cells; Biolegend: Table S2). Cells were washed three times in Cell Stain Buffer (BioLegend) and concentrated by pelleting and resuspended in a smaller volume prior to Chromium chip loading. Single-cell RNA-sequencing libraries were then prepared from isolated cells using the Chromium Single cell 3’ Solution V2 or V3 kit (10x Genomics) following the manufacturer’s protocol by the Genomics Core Facility UCSF Institute for Human Genetics (Table S2). For CITE-seq samples, 0.2 pmol of ADT (antibody derived tag) additive primer was added at the RNA library cDNA amplification step. CITE-seq libraries were prepared according to the manufacturer’s TotalSeq-A antibody protocol (BioLegend). In brief, 70 µL of ADT-containing cDNA amplification supernatant was purified with two rounds of 2X SPRI beads (Beckman-Coulter) and then amplified for 14-20 cycles using HiFi HotStart ReadyMix (KAPA, Roche Sequencing & Life Science) and 0.25 µM of oligos corresponding to SI PCR primer and Truseq Small RNA RPI1-6 primers. The resulting amplification products were purified by 1.2X SPRI bead cleanup, then quantified with Qubit dsDNA HS Assay Kit. Quality for scRNA and ADT libraries was assessed by a TapeStation D1000 ScreenTape (Agilent Technologies Inc.) and quantitated by the Kapa library quantitation kit prior to sequencing. mRNA and ADT libraries were sequenced on a HiSeq 4000 (Illumina) with a read length configuration of 150 PE.

**Single cell RNA sequencing data processing**
FASTQ files derived from sequencing were aligned and quantified using Cell Ranger Software (v3.0.2, 10x Genomics) against the human GRCh38 reference transcriptome. A filtered data matrix was used which excludes empty droplets and doublets. Quality of cells were then assessed based on the total number of detected genes per cell and the percentage of mitochondrial gene counts. Cells were filtered if there were unique feature counts greater than 5000 or mitochondrial gene counts higher than 20%. Normalized counts were then computed based on feature counts for each cell divided by the total counts for that cell and multiplied by the scale factor (1e4) with natural-log transformation. Finally, about 500 to 6,000 cells per sample were retained for downstream analysis (Table S2). Based on these criteria, high-quality transcriptomic data was obtained from 68,835 single cells after removal of doublets and cells with high mitochondrial content or low number of genes. The median gene count per cell was 1351 post-filtering and the average total number of detected genes per donor was 18,048 (detailed sequencing metrics for each sample are in Table S2).
Dimensional reduction and unsupervised clustering

The harmony algorithm was used for batch effect correction and integration of cells into a coordinated space for unsupervised clustering. To detect high variable features (HVFs) used for harmony, the variance stabilizing transformation parameter was used as a function input. After scaling the data, a PCA matrix was calculated using detected HVFs with 20 components based on the ElbowPlot function in Seurat v4.0.2. We then provided this PCA matrix to the RunHarmony() function in Seurat using samples as technical covariates for correction. The batch-corrected coordinated space then was used to compute the nearest neighbor graph by the FindNeighbors() function.

Indeed, across cell types prior to batch correction, samples clearly fell out as coherent clusters in the UMAP (Figure S1D), indicating that a large proportion of transcriptome-wide variation correlated to sample. However, upon batch correction, sample-specific cells no longer cohered but disease-level clusters continued to be clear (Figure S1D). We therefore concluded that sample-level batch correction successfully eliminated potential sample-level confounding while preserving target disease-level variation.

This nearest neighbor graph was used by FindClusters() using the Louvain algorithm for clustering of cell populations and dimensional reduction such as UMAP and tSNE. Based on clustree optimization, we utilized resolution = 0.4 to obtain 14 initial immune clusters (6 CD3+ or KLRRB1+ lymphocyte and 8 HLA-DRA+ antigen presenting cell clusters). We grouped the lymphocyte cell clusters independently and further subclustered them into 21 CD3+ or KLRRB1+ clusters to achieve finer resolution. To filter out cells containing markers previously identified as associated with collagenase digestion, and thus representing potential artifacts, we removed clusters 15 and 21 (as numbered in the Seurat object), which were highly enriched for JUN, FOS, HSPA1B, and HSP1B. We retained for analysis the six major T cell populations that each represented more than 5% of all T cells from our sample dataset. Cluster-specific differentially expressed genes were detected using the FindMarkers() function in the Seurat package using the MAST method and manually annotated based on the expression of known marker genes and then were checked using the singleR package v3.13.

The Human Primary Cell Atlas was used as a reference dataset for annotation.

To identify genes differentially expressed between psoriasis and matched normal samples, we developed pseudo-bulk counts for each cluster in each patient using the Bioconductor package muscat, which then applies edgeR to detect statistically significant differences between the patient groups.

To deconvolute CD4+ and CD8+ T cells in the Trm1 population, we took a conservative transcriptional gating approach to ensure that we called high-confidence helper and cytotoxic T-cells. We used empiric unimputed data, filtering out non-expressing or double positive cells (double positive were defined as cells expressing CD4/CD8A and/or CD4/CD8B). We then defined CD4+ cells as those expressing detectable CD4 transcripts and CD8+ cells as those expressing either CD8A or CD8B transcripts. For analysis in Figure 6, all cells containing at least one IL17A+ or IL17F+ read were counted and then corrected for sampling of the overall. The correction factor was (total CD4+ cells isolated in the biopsy/total CD4+ cells profiled by scRNA-seq).

scRNA-seq correlation analysis

To identify genes associated with ZFP36L2 expression, we used Spearman rank correlations to search through cluster-specific sets of high variability genes. First, we identified the top 5000 variable genes across cells within sample- and cluster-specific subpopulations using the Seurat function FindVariableFeatures. Within these cell subpopulations, we then tested for the association between ZFP36L2 and each of these highly variable genes with Spearman correlations implemented in the cor.test function from the Stats package v3.6.2. We accounted for multiple testing by adjusting p-values with the Benjamini-Hochberg procedure.

For Figures 2A, 2B, and 4A, the standard imputed expression value shown on the x-axis represents count data that has been normalized and log-transformed by R/Seurat’s default standardization and normalization algorithms, and imputed by R/iCellR/ run.impute(my.obj, dims = 1:10, nn = 10, data.type = pca).

Trm1 manifold and developmental trajectory inference

We analyzed Trm1 subpopulation cells with the goal of understanding how unbiased developmental trajectories could be inferred from them, using these spatially separate subjects as a space-for-time substitutions (i.e. how cells could develop from uninflamed to inflamed states using samples separated in space among different subject to infer temporal transitions in pseudotime). Since human subjects differ in a number of potentially confounding ways, we controlled for sample-level variation by implementing a mutual nearest neighbor batch correction routine to ‘regress out’ the effect of sample-specific variation, presuming that the residual variation would be produced by disease-level rather than sample-level variation. Indeed, this proved to be the case since disease correlated strongly to axes 1 and 2 of the resulting uMAP, indicating that the plurality of variation in the data after accounting for sample-specific variation correlated to disease state. We then undertook a manifold optimization routine to balance local and global structure in the data based on: 1) global connectedness to support the inference of a global trajectory and 2) local clustering to isolate specific disease- and cell-state subpopulations.

First, we re-composed Trm1 cells in a uMAP, exploring 3,000 combinations in Nn (number of nearest neighbors [5,50] and Md (minimum nearest neighbor distance [0.1,0.9]), finding 10 and 0.8 respectively to strike the best balance between global and local information on manual inspection. We then used Leiden-based clustering at default resolution (k=10, partition q-value=0.05) to call unsupervised clusters for downstream lineage inference.

Since the true branching structure and hierarchy in Trm1 cells are unknown, we used Monocle3 to infer a rooted trajectory since it has been benchmarked in controlled trials as the most informative and robust method to interrogate complex developmental topologies in single cells. We then used the Monocle3/learn_graph function without partition-consideration to infer a global trajectory. We then...
overlaid clinical information on the uninflamed or inflamed provenance of each cell onto the manifold, knowing that the true trajectory begins with uninflamed cells. Node 1 occurred in a highly dense cluster of uninflamed cells oriented along axes 1 and 2 away from the majority of inflamed cells, and thus, we rooted our global trajectory in this node and calculated pseudotemporal ordering from it using the order_cells function in Monocle3. We then observed that pseudotemporal order and ZFP36L2 expression were broadly correlated to Axis 1 and testing for the Spearman rank correlation between them revealed a significant anticorrelation. Since this result concords with inflammation-associated downregulation in ZFP36L2 observed in clinical specimens, we considered this topology to reflect true ZFP36L2-associated dynamics in these cells. We then repeated these associations by integrating over specific sets of genes using the aggregate_gene function in Monocle3 without maximum or minimum cutoffs. These scaled, integrated gene expression values enabled the direct comparison of the total expression of sets of genes among cells with a single value, which were overlaid on the manifold and correlated with pseudotime as in Figure 5. The association between the integrated expression of these programs and pseudotime were not linear and thus we fit LOESS curves to visualize overall trends.

Combinatorial single-cell inflammatory mediator prediction analysis

Since the aggregation of gene sets smoothed over gene-level variation within these sets, it was not clear which constituent genes within a set may be driving correlational patterns observed in Figure 6. In order to test this directly, we implemented a combinatoric approach to test the correlation of all possible, non-repeating combinations of genes of all set sizes between predictive sets and single response genes. The predictive set consisted of ZFP36L2, ZFP36, CCL22, SOCS1, SOCS3, BTG1, TXNIP, CD69; and the response genes were IL17A, IL17F, IL26, INFγ, CXCL13, CD2, CD3E, CD3G, CD82, TFCR, LAYN, GNLY, ENTPD1, CPM, NPDC1, ZEB2. Gene values were batch-corrected at the sample level using the CPCA method in the R package iCellR; missing gene values were independently imputed within inflamed and uninflamed states of sample-aligned matrices using the PCA method in iCellR/run.impute. Resulting matrices were then passed to Monocle3, and all possible combinations of predictor genes were then summed using the aggregate_gene function, and their correlation with response genes calculated with Spearman rank correlations using the cor.test function.

To develop pairwise statistical tests of the predictive power of these ZIST gene combinations, we developed a stepwise model comparison algorithm using R/cocor. We used this package to implement a two-sided test between the correlations of independent variables (in this case the gene sets). This method relies on Hitnner, May, and Silver’s modification of Dunn and Clark’s Z statistic, which in turn uses a backtransformed Fisher’s Z procedure. To control type 1 error by shrinking the test space, we ordered pairwise steps according to correlation coefficients of gene sets and tested for correlation differences only between two adjacent gene sets.

Preparation of CRISPR/Cas9 Ribonucleoprotein particles

Five gRNAs, two each for ZFP36L2 and ZFP36 and one targeting the AAVS1 locus with the following sequences were utilized:

L2g1: 5' - CGCGGTTTCTCCTAAAGAG -3'
L2g2: 5' - CTGCCACTTCCATCCACAACG -3'
36g1: 5' - GCTACAAGACTGAGCTATGT -3'
36g2: 5' - CAACCTTAGCAAGACCTGG -3'
AAVS1: 5' - GGGACACCTATATTTCCA -3'

gRNAs and trans-activating crRNA (tracrRNA, IDT technologies) were resuspended to 160 μM in Duplex Buffer (IDT technologies), mixed in equimolar quantities, heated to 95°C for 5 min and cooled slowly to room temperature to facilitate annealing of the oligomers. Polyglutamatic acid (15-50 kDa) was added to a final concentration of 2 mg/mL followed by addition of Cas9-NLS (QB3 MacroLab, University of California, Berkeley) to a final concentration of 10 μM. The ribonucleoprotein particles (RNPs) were incubated for 15 min at 37°C then stored at 4°C prior to nucleofection the same day.

Donor T cell nucleofection

T cells were isolated from donor leukopaks (STEMCELL Technologies) by negative selection with CD3 magnetic beads (EasySep Human T Cell Isolation Kit; STEMCELL Technologies) according to the manufacturer’s protocol and frozen in LN2 at 20x10⁶ cells/mL for storage. Donor T cells were then thawed, washed twice in X-VIVO 15 media (Lonza) then resuspended at 1x10⁶ cells/mL in T cell medium (X-VIVO 15 supplemented with 5% FBS, 55 μM 2-mercaptoethanol and 200 IU/mL recombinant human IL2) prior to the addition of CD3/CD28 conjugated magnetic activation beads (Dynabeads; Invitrogen) at a 1:1 bead-to-cell ratio. Forty-eight hours later the cells were washed 1x in PBS, resuspended in 20 μL of supplemented P3 nucleofection solution (Lonza) at 50x10⁶ cells/mL, and immediately added to the RNPs and mixed by gentle pipetting. The cell/RNP mixture was placed in one well of a 16-well cuvette strip (P3 Primary Cell 4D-Nucleofector X Kit S; Lonza) and electroporated using program EH115 on a Lonza X-Unit nucleofector. Immediately after, 100 μL of warm X-VIVO+5% FBS was added to the well, and the cells were placed in a 5% CO2 incubator at 37°C for 15 min, then plated in 4 mL of T cell medium. Cells were monitored daily and split 1:1 when the density reached 2x10⁶ cells/mL or media showed signs of acidification.

PCR-based validation of CRISPR-based T cell gene knockout

Genomic DNA was extracted from edited primary T cells seven days after nucleofection using a Wizard Genomic DNA Purification Kit (Promega). A ~500 bp fragment flanking the CRISPR/Cas9 cut site for each knockout and gene was then amplified by PCR, utilizing the following primer pairs:
RNA transcript abundance was quantified with Kallisto version 0.46.156 using 100 bootstraps and a prebuilt index based on Bulk RNA-seq analysis for 40 M PE reads per sample (20M in each direction). QC values and sequenced on an Illumina NovaSeq S4 (Illumina) with a read length configuration of 150 PE library size was about 400 bp with an insert size of about 280bp. Illumina 8-nt dual-indices were used. Libraries were quantified using NEBNext UltraTM II Non-Directional RNA Library Prep Kit for Illumina (New England BioLabs Inc.). Libraries were quantified by Qubit 2.0 (ThermoFisher) and quality assessed by TapeStation HSD1000 ScreenTape (Agilent Technologies Inc). Average final library size was about 400 bp with an insert size of about 280bp. Illumina 8-nt dual-indices were used. Equimolar pooling of libraries by Qubit 2.0 (ThermoFisher). Total RNA was combined with paramagnetic beads coupled with oligo d(T)25 to isolate poly(A)+ transcripts using the Poly(A) mRNA Magnetic Isolation Module (New England BioLabs Inc.). Prior to first strand synthesis, samples were diluted 1:40 dilutions Abs to the following intracellular cytokines: APC zHuman IFNγ clone 4S.B3 (Biolegend #502512), FITC zHuman TNFα clone MAb11 (Biolegend #502906) and PerCP/Cyanine5.5 zHuman IL-2 clone MQ1-17H12 (Biolegend #500322). Samples were then washed and data was collected on an Attune Nxt Cytometer (UCSF LCA Core) and analyzed with FlowJo (BD).

Intracellular cytokine assays of CRISPR-modified T cells

T cells were seeded in 200 μL of X-VIVO supplemented with 5% FBS in a 96-well U-Bottom plate at 2.5x10^6 cells/mL. PMA + ionomycin resuspended in DMSO was added to give final concentrations ranging from 50 pg/mL to 50 ng/mL PMA and 0.1 ng/mL to 10 ng/mL ionomycin and the cells were incubated for 5 h at 37°C. After 1 h, 1 μL each of a 1:5 dilution of Brefeldin A (BioLegend) and Monensin (BioLegend) in X-VIVO+5%FBS was added. The cells were then washed 1X in PBS and resuspended in Zombie Aqua Live/Dead (Biolegend) diluted 1:100 in PBS and incubated at room temperature for 15 min in the dark. Cells were then washed 2X in FACS buffer and resuspended in 100 μL of FACS buffer containing 1:1 dilutions of both PE zHuman CD4 Clone OKT4 (Biolegend #317410) and BV711 zHuman CD8 Clone RPA-T8 (Biolegend #301044), then incubated for 20 min at 4°C. Cells were then fixed and permeabilized (CytoFix/CytoPerm; BD) according to manufacturer’s instructions and resuspended in 100 μL Perm/Wash buffer containing 1:40 dilutions Abs to the following intracellular cytokines: APC zHuman IFNγ clone 4S.B3 (Biolegend #502512), FITC zHuman TNFα clone MAb11 (Biolegend #502906) and PerCP/Cyanine5.5 zHuman IL-2 clone MQ1-17H12 (Biolegend #500322). Samples were then washed and data was collected on an Attune Nxt Cytometer (UCSF LCA Core) and analyzed with FlowJo (BD).

mRNA isolation and bulk RNA-seq of CRISPR-modified CD4+ T cells

Nucleofected T cells as described above were washed 1x in FACS buffer then stained with cell surface antibodies to CD4 (PE Human CD4 Clone OKT4; Biolegend #317410) for 30 min at 4°C. After washing unbound antibody, DAPI was added at 10 μg/mL and CD4+ cells were sorted into X-VIVO+20% FBS after gating for live singlets. The cells were then washed in X-VIVO supplemented with 5% FBS and 5 μM 2-mercaptoethanol and were incubated in a 5% CO2 incubator at 37°C. On the day of the experiment, 1x10^6 cells were plated in 1mL of X-VIVO media supplemented with 5% FBS and 0.5 ng/mL PMA+10 ng/mL ionomycin for 4 h in a CO2 incubator at 37°C. Following incubation, the cells were pelleted and resuspended in 750 μL TRIzol Reagent (Invitrogen). RNA extraction and DNase treatment was carried out using a Direct-zol RNA Miniprep kit (Zymo Research) according to manufacturer’s instructions. RNA sample quality was assessed by the Bioanalyzer Pico kit (Agilent Technologies Inc.) and quantified by Qubit 2.0 RNA HS assay (ThermoFisher). Total RNA was combined with paramagnetic beads coupled with oligo d(T)25 to isolate poly(A)+ transcripts using the NEBNext® Poly(A) mRNA Magnetic Isolation Module (New England BioLabs Inc.). Prior to first strand synthesis, samples were randomly primed and fragmented per manufacturer’s recommendations. The first strand was synthesized with the Protocscript II Reverse Transcriptase for 30 min at 42°C. All remaining steps for library construction were performed per the manufacturer’s protocol for the NEBNext UltraTM II Non - Directional RNA Library Prep Kit for Illumina (New England BioLabs Inc.). Libraries were quantified by Qubit 2.0 (ThermoFisher) and quality assessed by TapeStation HSD1000 ScreenTape (Agilent Technologies Inc). Average final library size was about 400 bp with an insert size of about 280bp. Illumina 8-nt dual-indices were used. Equimolar pooling of libraries was performed based on QC values and sequenced on an Illumina NovaSeq S4 (Illumina) with a read length configuration of 150 PE for 40 M PE reads per sample (20M in each direction).

Bulk RNA-seq analysis

RNA transcript abundance was quantified with Kallisto version 0.46.156 using 100 bootstraps and a prebuilt index based on Ensemble v96 from https://github.com/pachterlab/kallisto-transcriptome-indices. Differential expression (DE) analysis was performed with sleuth version 0.30.0 [1] in gene mode. Likelihood-ratio tests were used to compare sleuth models fit with both treatment and donor as covariates against models that only used the donor covariate. Genes were selected for DE testing based on a threshold of log2(normalized TPM +1) > 1 in at least half of the samples. Of the genes passing the expression filter, the 2000 genes with highest log2-TPM variance were used. We performed gene set enrichment analysis using fgsea v1.12.0 [5] with a max gene set size of 500 and 100,000 permutations. 2922 gene sets from canonical pathways in the curated gene sets collection from MSigDB v7.4 [5] were used in the enrichment analysis.

L2g1-F = 5’ CTCAACCTGAAACACATGC 3’
L2g1-R = 5’ TGACTCTGATGCGA 3’
L2g2-F = 5’ AGCGAGAACGCCATC 3’
L2g2-R = 5’ GGCTTGGACGCGAC 3’
36g1+36g2-F = 5’ GTCACCAGCCTGATGG 3’
36g1+36g2-R = 5’ GGCTCTCTGGAGCCAGG 3’
AAVS1-F = 5’ TCGTGAGATCGGTTCA 3’
AAVS1-R = 5’ GTCCTAGTGAAAGCTCT 3’

PCR amplifications were carried out using Phusion High-Fidelity DNA Polymerase (ThermoFisher) with reagent concentrations specified in the product catalog. Thirty-five cycles were run with a denaturation time of 30 s at 98°C, followed by an annealing step for 30 s at varying temperatures to match specific primer Tms, followed by an elongation step at 72°C for 30 s. Single band PCR products were purified using a PCR Purification Kit (Qiagen) while PCR products with more than one band were gel extracted (Qiagen Gel Purification Kit). Edited samples and non-targeting controls underwent Sanger sequencing (Quintara Biosciences) utilizing a primer specific for the target locus. Resulting AB1 files were imported into the online ICE algorithm portal (Synthego) and assessed for knockout efficiency.

mRNA isolation and bulk RNA-seq of CRISPR-modified CD4+ T cells

Nucleofected T cells as described above were washed 1x in FACS buffer then stained with cell surface antibodies to CD4 (PE Human CD4 Clone OKT4; Biolegend #317410) for 30 min at 4°C. After washing unbound antibody, DAPI was added at 10 μg/mL and CD4+ cells were sorted into X-VIVO+20% FBS after gating for live singlets. The cells were then washed in X-VIVO supplemented with 5% FBS and 5 μM 2-mercaptoethanol and were incubated in a 5% CO2 incubator at 37°C. On the day of the experiment, 1x10^6 cells were plated in 1mL of X-VIVO media supplemented with 5% FBS and 0.5 ng/mL PMA+10 ng/mL ionomycin for 4 h in a CO2 incubator at 37°C. Following incubation, the cells were pelleted and resuspended in 750 μL TRIzol Reagent (Invitrogen). RNA extraction and DNase treatment was carried out using a Direct-zol RNA Miniprep kit (Zymo Research) according to manufacturer’s instructions. RNA sample quality was assessed by the Bioanalyzer Pico kit (Agilent Technologies Inc.) and quantified by Qubit 2.0 RNA HS assay (ThermoFisher). Total RNA was combined with paramagnetic beads coupled with oligo d(T)25 to isolate poly(A)+ transcripts using the NEBNext® Poly(A) mRNA Magnetic Isolation Module (New England BioLabs Inc.). Prior to first strand synthesis, samples were randomly primed and fragmented per manufacturer’s recommendations. The first strand was synthesized with the Protocscript II Reverse Transcriptase for 30 min at 42°C. All remaining steps for library construction were performed per the manufacturer’s protocol for the NEBNext UltraTM II Non - Directional RNA Library Prep Kit for Illumina (New England BioLabs Inc.). Libraries were quantified by Qubit 2.0 (ThermoFisher) and quality assessed by TapeStation HSD1000 ScreenTape (Agilent Technologies Inc). Average final library size was about 400 bp with an insert size of about 280bp. Illumina 8-nt dual-indices were used. Equimolar pooling of libraries was performed based on QC values and sequenced on an Illumina NovaSeq S4 (Illumina) with a read length configuration of 150 PE for 40 M PE reads per sample (20M in each direction).

Bulk RNA-seq analysis

RNA transcript abundance was quantified with Kallisto version 0.46.156 using 100 bootstraps and a prebuilt index based on Ensemble v96 from https://github.com/pachterlab/kallisto-transcriptome-indices. Differential expression (DE) analysis was performed with sleuth version 0.30.0 [1] in gene mode. Likelihood-ratio tests were used to compare sleuth models fit with both treatment and donor as covariates against models that only used the donor covariate. Genes were selected for DE testing based on a threshold of log2(normalized TPM +1) > 1 in at least half of the samples. Of the genes passing the expression filter, the 2000 genes with highest log2-TPM variance were used. We performed gene set enrichment analysis using fgsea v1.12.0 [5] with a max gene set size of 500 and 100,000 permutations. 2922 gene sets from canonical pathways in the curated gene sets collection from MSigDB v7.4 [5] were used in the enrichment analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis for flow cytometry data
Data is presented as mean ± SEM Statistical differences between groups were calculated with Student’s two-sample, two-tailed, homoscedastic t-test as outlined in the Figure Legends. Significance is denoted by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Statistical analysis for scRNA-seq and bulk RNA-seq data
Detailed and comprehensive statistical parameters underlying the analysis of scRNA-seq and bulk RNA-seq data can be found in Method details and corresponding figure legends.